Compounded vs. Brand-Name Semaglutide in 2026: What Georgia Patients Should Know

By Dr. Don Gates, MD, Founder of Scale Solutions

Compounded semaglutide and brand-name semaglutide are not the same product, and the difference is regulatory rather than a simple matter of real versus fake. Brand-name Wegovy and Ozempic are FDA-approved drugs, meaning the agency reviewed the manufacturer’s evidence for identity, purity, potency, sterility, dosing, and clinical effect before allowing them on the market. Compounded semaglutide is prepared by a pharmacy or an outsourcing facility and is not FDA-approved — not because FDA reviewed it and rejected it, but because compounded drugs are not reviewed at all.

That distinction has always been true. What changed is the legal ground under it. The shortage conditions that allowed large-scale compounding of semaglutide and tirzepatide have ended, and in 2026 the FDA took several significant actions affecting this market — including one major proposal that is still pending as of August 19, 2026.

Key Takeaways

• Compounded is not FDA-approved. No compounded drug is. That is a statement about regulatory review, not an automatic statement about any individual pharmacy’s quality.
• The shortage justification is gone. Tirzepatide came off the FDA shortage list in 2024 and semaglutide in February 2025, which removed the legal basis most large-scale compounding relied on.
• The biggest 2026 development is still a proposal. FDA has proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List. The comment period closed July 30, 2026. No final decision has been issued.
• FDA’s practical concerns are specific and worth knowing: dosing errors (especially units versus milligrams), improper shipping and storage, mislabeled products, and semaglutide salt forms that are chemically different from the approved drug.
• Ask five questions and you will know where you stand. They are listed below, and they work with any provider, in person or online.

What “Compounded” Actually Means

Compounding is the preparation of a medication by a licensed pharmacist or facility to meet a need an FDA-approved product does not — a liquid version of a pill for someone who cannot swallow, a formulation without a dye a patient reacts to. It is a legitimate, long-standing part of American medicine, and compounded drugs are legal. They are simply governed by a different section of federal law than approved drugs, and that difference matters more than most marketing suggests.

503A Pharmacies vs. 503B Outsourcing Facilities

These two categories are frequently blurred together, including by companies selling the product. They are not the same thing.

Two consequences follow. A 503B outsourcing facility operates under a manufacturing-quality standard that a 503A pharmacy does not. And — the part patients almost never hear — because state-licensed 503A pharmacies are not required to report adverse events to FDA, the national safety data on compounded GLP-1s is systematically incomplete. FDA says so directly.

The Three-Condition Test for 503A Pharmacies

A 503A pharmacy cannot compound using just any bulk drug substance. Federal law allows a bulk substance only if it meets one of three conditions:

1. It has a USP or NF monograph (a published, official quality standard), or
2. It is a component of an FDA-approved drug, or
3. It appears on FDA’s 503A bulks list.

This is why the phrase “it’s on the FDA list” gets used loosely in marketing. Meeting one of these three conditions is a threshold requirement about the raw ingredient. It is not FDA approval of the finished compounded medication, and it does not mean FDA has evaluated that product’s safety or effectiveness.

Section 503A separately restricts compounding a drug that is essentially a copy of a commercially available drug product. While a drug is in shortage, that restriction is applied differently. Once the shortage resolves, it becomes the operative limit — which is exactly what happened here.

Why the Shortage History Matters

Demand outstripped supply beginning in 2022. FDA placed both drugs on its shortage list, and under shortage conditions compounders were permitted to prepare versions at a scale that would not otherwise have been allowed. For a real period of time, compounded semaglutide was how many patients got treated at all. That is genuine history and should not be rewritten.

Then supply recovered:

• October 2, 2024 — FDA determined the tirzepatide injection shortage resolved; reaffirmed by a new decision on December 19, 2024.
• February 21, 2025 — FDA determined the semaglutide injection shortage resolved.
• FDA set end dates for its enforcement discretion: for tirzepatide, February 18, 2025 (503A) and March 19, 2025 (503B); for semaglutide, April 22, 2025 (503A) and May 22, 2025 (503B).

(FDA compounding policy page, content current as of April 1, 2026.)

Liraglutide injection has continued to appear on the shortage list. Semaglutide and tirzepatide have not been in shortage for well over a year. When a company today explains its compounded semaglutide as a response to a shortage, that explanation no longer describes the current supply situation.

The 2026 Regulatory Picture

Four developments define where things stand as of August 19, 2026.

1. The 503B Bulks List proposal — pending, not final

On April 30, 2026, FDA announced, and on May 1, 2026 published in the Federal Register (Docket FDA-2018-N-3240), a proposal to not include semaglutide, tirzepatide, and liraglutide on the 503B Bulks List. FDA’s stated reasoning was that there is no clinical need for outsourcing facilities to compound these substances, and no basis to conclude the FDA-approved products are medically unsuitable for patients.

FDA made one point explicitly that is worth repeating: patient preference does not establish clinical need. Preferring a different dose increment, a vial instead of a pen, or a lower price is not, in FDA’s framing, a clinical justification.

The comment period was extended by a notice on June 26, 2026 and closed July 30, 2026. As of August 19, 2026, FDA has issued no final determination, and no statutory deadline forces one. Anyone telling you this question is settled — in either direction — is ahead of the record.

2. Warning letters to 30 telehealth companies — March 3, 2026

FDA issued warning letters to 30 telehealth companies over the marketing of compounded GLP-1s, following an earlier action in September 2025. Two violations were cited, and both are directly useful to patients:

• Claims implying the compounded product is equivalent to the FDA-approved version. It is not, and saying so is a labeling violation.
• Branding the compounded drug with the telehealth company’s own name or trademark, without disclosing who actually compounded it — so the patient could not tell which pharmacy made the medication going into their body.

FDA Commissioner Marty Makary, in the agency’s announcement: “Compounded drugs can be important for overcoming shortages or meeting unique patient needs—but compounders should not try to compound drugs in a way that circumvents FDA’s approval process.”

That is a fair summary of the agency’s position, and note what it is not: it is not a statement that compounding is inherently unsafe.

3. Import Alert 66-80

FDA established Import Alert 66-80, a “green list” alert intended, in the agency’s words, “to help stop GLP-1 active pharmaceutical ingredients (APIs) that have potential quality concerns from entering the U.S. supply chain.” The raw ingredient supply is a real point of vulnerability, and much of it is imported.

4. Adverse event reports

As of May 31, 2026, FDA had received 990 adverse event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide.

Read those numbers carefully. FDA states the true totals are likely higher, because state-licensed pharmacies are not required to report. At the same time, raw report counts do not establish causation and are not directly comparable to approved-product reporting volumes. These are signals worth taking seriously, not a measured rate of harm.

FDA’s Specific Safety Concerns — and Why the Dosing One Matters Most

FDA’s advisory on unapproved GLP-1 drugs (content current as of June 15, 2026) lists concerns that are concrete rather than theoretical:

Dosing errors. This is the one I would want any patient to understand. Brand-name pens deliver a fixed dose. Many compounded products arrive as a vial plus a syringe, and the patient measures the dose themselves. Insulin syringes are marked in units, but semaglutide is dosed in milligrams. If a vial is labeled in milligrams per milliliter and the instructions are given in units — or if a patient reads “5” on a syringe as 5 mg — the resulting dose can be off by a factor of ten. FDA has received multiple reports of adverse events, some requiring hospitalization, that may relate to dosing errors with compounded injectable semaglutide.

Improper storage and shipping. Injectable GLP-1s require refrigeration, and FDA advises patients not to use any that arrives warm or insufficiently refrigerated. Shipping a temperature-sensitive product through a Coastal Georgia summer is not a trivial logistics problem.

Semaglutide salt forms. Some products contain semaglutide sodium or semaglutide acetate. In FDA’s words, these “are different active ingredients than are used in the approved drugs,” and their safety and effectiveness have not been established.

Fraudulent or mislabeled products from pharmacies that are unlicensed or do not exist at all.

“Research purposes only” products. FDA has warned companies selling products labeled “for research purposes” or “not for human consumption” while providing dosing instructions and selling direct to consumers. If a product’s own label says it is not for human consumption, that label is telling you something important.

FDA also states plainly that retatrutide and cagrilintide cannot legally be used in compounding — worth knowing given how often those names now appear in marketing.

What Is Genuinely True in Compounding’s Favor

A one-sided article would not be useful, and it would not be accurate.

Cost is a real difference, not an imaginary one. For patients paying entirely out of pocket, compounded products have generally been meaningfully cheaper. That is the whole reason this question exists, and dismissing price as a frivolous consideration is not how actual patients make decisions.

The shortage-era access was legitimate. Patients who started compounded semaglutide in 2023 or 2024 were not doing something wrong. That pathway operated within FDA’s stated enforcement approach at the time.

Many compounding pharmacies operate lawfully and carefully, filling genuine clinical gaps every day. The problems FDA has documented cluster around a specific corner of this market — high-volume direct-to-consumer sales of copies of approved drugs — not around compounding as a practice.

Individualized compounding still has a defined legal lane. Section 503A contemplates circumstances where a patient has a documented clinical need an approved product cannot meet. Whether a particular product qualifies is a regulatory determination made case by case by FDA and state boards of pharmacy — not something a marketing page can settle.

What to Ask Before You Take a Compounded GLP-1

If you take nothing else from this article, take this list. These questions work with any provider — a local practice, a med spa, or an online program — and the answers should be immediate and specific.

1. Is the medication you are prescribing brand-name or compounded? Ask it directly and get a direct answer. This is the single most useful question, and many patients do not know which one they are taking.
2. If it is compounded, which pharmacy compounds it — by name — and is it a 503A pharmacy or a 503B outsourcing facility? If the product is branded only with the telehealth company’s name, ask again. That was one of the two violations FDA cited in March 2026.
3. Is that pharmacy licensed in Georgia? Georgia’s Board of Pharmacy licenses in-state pharmacies and registers nonresident pharmacies shipping into the state. You are entitled to know.
4. What is the concentration, and exactly how do I measure my dose? Get the concentration in milligrams per milliliter, the volume to draw, and a demonstration. Confirm whether your instructions are in units or milligrams. If anyone tells you “just draw to the 10,” ask what that means in milligrams.
5. How should this be stored, and what do I do if it arrives warm? There should be a clear answer and a named person to call.
6. Who do I contact if I have a side effect or a reaction — and how fast can I reach an actual clinician? Not a chat queue. A clinician.

You can also report problems yourself to FDA’s MedWatch program, which is open to patients and does not require going through a provider.

Related: in-person care versus an online GLP-1 program.

The Cost Comparison, Honestly

The brand-name price picture in 2026 is genuinely different from 2023, and many patients are working from outdated numbers. Manufacturer direct-to-consumer self-pay pricing has come down substantially.

Prices verified August 19, 2026. These programs change frequently — confirm current pricing before making a decision.

With commercial insurance that covers the medication, manufacturer programs can bring costs as low as $25/month. A federal direct-purchase storefront also lists Zepbound starting at $299/month, Wegovy pen at $199/month, and Wegovy tablets at $149/month.

I am deliberately not publishing compounded price figures. There is no authoritative primary source for them — they vary by seller and change constantly — and quoting them would amount to a price list for products I cannot verify. What I can tell you is that the gap is narrower than it was, and that a patient comparing options should price the actual brand-name product at their actual dose before assuming they cannot afford it.

Why This Decision Is Sharper in Georgia

Georgia Medicaid does not cover weight-loss medications. The state’s approved plan amendment (GA-24-0001, effective January 1, 2024) lists “Agents used for anorexia, weight loss or weight gain” among excluded outpatient drug categories, and the Georgia Preferred Drug List effective August 1, 2026 confirms it — Wegovy, Zepbound, Saxenda, Contrave, Qsymia, phentermine, and orlistat do not appear. Semaglutide and liraglutide appear only in the diabetes class. As of January 2026, Georgia was not among the 13 state Medicaid programs covering GLP-1s for obesity. Georgia has also not expanded Medicaid; the Pathways to Coverage program had 8,077 active enrollees as of June 30, 2025, against roughly 240,000 uninsured low-income adults statewide.

The practical result across Chatham, Bryan, Effingham, and Liberty counties: a large share of people seeking GLP-1 treatment are paying out of pocket. When you are self-pay, the price difference between a compounded and a brand-name product is not an abstraction — it is your monthly budget. That is precisely why the question deserves accurate information rather than marketing.

When to Talk to Your Doctor

Seek emergency care immediately — call 911 or go to the nearest emergency department — for signs of a severe allergic reaction (trouble breathing, swelling of the face, lips, or throat, widespread hives), severe and persistent abdominal pain that may radiate to the back and is often accompanied by vomiting, or symptoms of severe low blood sugar such as confusion, loss of consciousness, or seizure.

Contact your clinician promptly, the same week, if you:

• Are not certain whether your medication is brand-name or compounded, or cannot identify the pharmacy that made it
• Received a vial that arrived warm, looks cloudy or discolored, or has particles in it
• Are unsure whether you are measuring your dose correctly, or realize you may have taken more than intended
• Received a product labeled “semaglutide sodium,” “semaglutide acetate,” “for research purposes only,” or “not for human consumption”
• Have new or worsening nausea, vomiting, or dehydration keeping you from eating and drinking normally
• Are considering switching between compounded and brand-name product — dose equivalence is not automatic, and this is worth planning rather than improvising

Do not stop a prescribed medication on your own based on a news headline. If something you have read concerns you, the right next step is a conversation with a clinician who can look at your specific product, your dose, and your medical history.

Scale Solutions & Coastal Georgia

This is a question where knowing a patient over time genuinely changes the answer. The right medication, dose, and source depend on your history, your other prescriptions, your insurance, what you can realistically afford month after month, and how you have tolerated treatment so far. Those things are not visible from an intake form.

Our work with patients across Savannah, Pooler, Richmond Hill, Hinesville, Rincon, and Statesboro is built around ongoing follow-up — reviewing what you are actually taking, monitoring how you respond, adjusting when something is not working, and helping you navigate cost rather than treating price as somebody else’s problem. Continuity is not a marketing feature here; it is the part that makes treatment work over years rather than months.

If you live in Savannah or Coastal Georgia and you are not sure what is in the vial or pen you have been prescribed — or you want an unbiased read on your options before you commit — you are welcome to reach out. We are glad to talk it through, including with people who are currently established elsewhere and simply want a second opinion.

Related: how semaglutide is prescribed and monitored.

Related: what GLP-1 treatment actually costs in Georgia.

Related: what the FDA safety data actually shows for GLP-1s.

Related: check whether you meet clinical criteria.

Related: semaglutide compared with tirzepatide.

Related: our editorial and sourcing policy.

Frequently Asked Questions

Is compounded semaglutide the same as Wegovy or Ozempic? No. Wegovy and Ozempic are FDA-approved products that were reviewed for identity, purity, potency, and clinical effect. Compounded semaglutide is not FDA-approved and was not reviewed. In March 2026, FDA cited 30 telehealth companies specifically for marketing claims implying the two are equivalent.

Did the FDA ban compounded semaglutide in 2026? No. FDA has proposed not to include semaglutide, tirzepatide, and liraglutide on the 503B Bulks List (Docket FDA-2018-N-3240, published May 1, 2026). The comment period closed July 30, 2026, and as of August 19, 2026 FDA has issued no final determination. It remains a pending proposal.

Is compounded semaglutide unsafe? That is not what the evidence supports, and it is not what FDA says. FDA has identified specific documented problems — dosing errors, improper shipping and storage, mislabeled or fraudulent products, and salt forms chemically different from the approved drug — concentrated in a particular part of the market. Many compounding pharmacies operate carefully and lawfully. The accurate framing is that compounded products carry a different and less-verified risk profile, and you should know which one you are taking.

How can I tell whether my medication is compounded? Brand-name products arrive in manufacturer packaging labeled Wegovy, Ozempic, Zepbound, or Mounjaro. Compounded products typically come as a vial with a pharmacy label, often with a separate syringe. If your medication is branded with the name of the company that sold it to you rather than a manufacturer or a named pharmacy, ask directly who compounded it.

Why is semaglutide dosed in milligrams but my syringe shows units? Insulin syringes are marked in units, a measure designed for insulin, not semaglutide. Semaglutide is prescribed in milligrams. Converting between them depends on the concentration of your specific vial, which is why a mismatch between the label and the instructions can produce a ten-fold error. If you are drawing your own dose, confirm the concentration and have someone walk you through the measurement in person.

What about compounded tirzepatide, retatrutide, or peptide blends? Tirzepatide came off the shortage list in 2024, so the same regulatory shift applies to it. Retatrutide and cagrilintide are different: FDA states plainly that they cannot legally be used in compounding. Retatrutide is still investigational and is not available by prescription in the United States.

I have been on compounded semaglutide for a year and I feel fine. Should I switch? That is a decision to make with a clinician who can review your specific product and dose, not a decision to make from an article. What is worth doing now is finding out exactly what you are taking and who makes it, then pricing the FDA-approved alternative at your actual dose. Many patients are surprised by how much the brand-name self-pay landscape changed in 2026.

Conclusion

Compounded and brand-name semaglutide are different things under the law, and in 2026 that legal difference has real weight behind it. The shortage that justified widespread compounding ended, FDA has proposed closing the outsourcing-facility pathway for these drugs, and the agency has documented specific problems worth understanding — particularly dosing errors and cold-chain failures. None of that makes every compounded product dangerous, and none of it is a reason to panic about a medication you have been taking safely. It is a reason to know exactly what you are taking, who made it, and how to measure it.

Not sure whether the vial in your refrigerator is compounded or FDA-approved — or whether switching between them makes sense for your budget and your dosing? Bring it to a physician in Coastal Georgia who will tell you plainly. Contact Scale Solutions. We will look at your specific prescription, your coverage, and your history, and give you the same answer we would want for a member of our own family. No pressure, and no obligation to change anything.

MEDICAL SOURCES & FURTHER READING

1. U.S. Food and Drug Administration. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Content current as of June 15, 2026. Source for adverse event counts as of May 31, 2026, dosing errors, salt forms, storage/shipping, “research purposes only” products, Import Alert 66-80, and the statement that retatrutide and cagrilintide cannot be used in compounding. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss

2. U.S. Food and Drug Administration. FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List. Press announcement, April 30, 2026. https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list

3. Federal Register. List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act. Docket FDA-2018-N-3240, published May 1, 2026. https://www.federalregister.gov/documents/2026/05/01/2026-08552/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal

4. Federal Register. …Extension of Comment Period. Published June 26, 2026; comment period closed July 30, 2026. https://www.federalregister.gov/documents/2026/06/26/2026-12937/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal

5. U.S. Food and Drug Administration. FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s. Press announcement, March 3, 2026. Source for the two cited violations and the Commissioner Makary quotation. https://www.fda.gov/news-events/press-announcements/fda-warns-30-telehealth-companies-against-illegal-marketing-compounded-glp-1s

6. U.S. Food and Drug Administration. FDA to Telehealth Companies: What to Know When Promoting Compounded Drugs. https://www.fda.gov/drugs/human-drug-compounding/fda-telehealth-companies-what-know-when-promoting-compounded-drugs

7. U.S. Food and Drug Administration. FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize. Content current as of April 1, 2026. Source for shortage resolution dates (tirzepatide October 2, 2024 and December 19, 2024; semaglutide February 21, 2025) and enforcement discretion end dates. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize

8. U.S. Food and Drug Administration. Compounding: Inspections, Recalls, and Other Actions. https://www.fda.gov/drugs/human-drug-compounding/compounding-inspections-recalls-and-other-actions

9. U.S. Food and Drug Administration. MedWatch: The FDA Safety Information and Adverse Event Reporting Program. Patient reporting pathway. https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program

10. Centers for Medicare & Medicaid Services. Georgia State Plan Amendment GA-24-0001, effective January 1, 2024; CMS-approved June 6, 2024. Source for the Georgia Medicaid exclusion of “Agents used for anorexia, weight loss or weight gain.” https://www.medicaid.gov/medicaid/spa/downloads/GA-24-0001.pdf

11. Georgia Department of Community Health. Georgia Medicaid Preferred Drug List, effective August 1, 2026. https://fm.formularynavigator.com/FBO/4/Georgia_PDL_English.pdf

12. Novo Nordisk / NovoCare Pharmacy and Eli Lilly / LillyDirect self-pay pricing pages. Prices verified August 19, 2026. https://www.novocare.com/ · https://zepbound.lilly.com/

13. Scale Solutions Editorial Policy — how we source and review medical content. https://scale-solutions.com/editorial-policy/